The billion-dollar, multi-program partnership between US pharmaceutical giant Pfizer (NYSE: PFE) and bioplatform innovation company Flagship Pioneering, initiated in July 2023, has expanded with two new additions. Ampersand Biomedicines and Montai Therapeutics, both Flagship-founded biotechs, have entered into agreements to identify targeted molecules aimed at treating obesity and non-small cell lung cancer (NSCLC). While financial details of these specific agreements were not disclosed, the overarching collaboration involved an initial investment of USD 50 million from each party to develop 10 candidate drugs, with Pfizer holding the rights to purchase.
Building on Existing Collaborations
Prior to these new agreements, Pfizer had already joined forces with another Flagship-founded company, ProFound Therapeutics, in June of this year to develop potential first-in-class obesity therapeutics. Following this, two months later, Pfizer began collaborating with Quotient Therapeutic, another Flagship offshoot, to analyze somatic mutations occurring in patient tissues. This collaboration aims to discover potential transformative therapies for cardiovascular and kidney diseases.
Expanding the Scope of Precision Medicine
These collaborations underscore Pfizer’s commitment to expanding the scope of precision medicine and targeted therapies. By partnering with Flagship-founded biotechs, Pfizer is leveraging innovative platforms to identify and develop new treatments for a range of diseases, from obesity to non-small cell lung cancer and beyond.-Fineline Info & Tech
Leave a Reply